vertex report cystic fibrosi cf revenu beat
consensu sequenti y/i driven part strong
uptak symdeko kalydeco revenu line consensu
orkambi/symdeko revenu orkambi symdeko beat
consensu non-gaap oper expens non-
gaap ep beat consensu vertex end period
cash
guidanc rais vertex increas cf revenu guidanc
reiter oper expens
reiter non-gaap oper expens
model adjust increas cf revenu estim
base increas revenu estim symdeko
came net effect non-gaap ep estim
increas
us launch symdeko demand strong uptak seen across
patient nave cftr modul
conclus vertex deliv anoth strong quarter cf revenu growth led
demand symdeko us approv expect europ
cf franchis continu grow focu remain tripl
potenti nda file
vertex leadership cf intact last month galapago glgp nr report
top-lin result pelican trial evalu corrector
orkambi combin treatment reach primari endpoint result
demonstr inferior lung function result adjust benefit treatment
vs placebo vs intern goal critic partner
nr decid proceed second plan triplet combin
studi review partnership contrast tripl combin
symdeko backbon vertex expect fulli
enrol nda file thu given lacklust data come
glgp advanc cf franchis vertex competitor vertex
remain well-posit continu domin cf space
upcom catalyst kalydeco yr old snda submiss pdufa
orkambi yr old snda submiss pdufa initi
europ transfus depend -thalassemia tdt possibl initi
us sickl cell diseas scd complet enrol
cf tripl data symdeco data
diversifi beyond cf first crispr-bas therapi
emerg collabor crispr crsp nr may
fda place clinic hold ind applic scd seek answer
addit question rose review ind
resolut hold second cta approv canada obtain
follow first uk trial europ adult patient
tdt expect delay start studi scd
us impact valuat vertex thesi center continu
growth cf pipelin
thousand except per share data
interest incom net
loss discontinu oper
net incom attribut vertex
compani report maxim group estim
